Back to Search
Start Over
Aprocitentan: First Approval.
- Source :
-
Drugs [Drugs] 2024 Jul; Vol. 84 (7), pp. 841-847. Date of Electronic Publication: 2024 Jun 04. - Publication Year :
- 2024
-
Abstract
- Aprocitentan (TRYVIO™) is a once-daily oral dual endothelin A (ET <subscript>A</subscript> ) and B (ET <subscript>B</subscript> ) receptor antagonist developed by Idorsia Pharmaceuticals for the treatment of hypertension. The endothelin pathway has been implicated in hypertension. Aprocitentan inhibits the binding of endothelin-1 to ET <subscript>A</subscript> and ET <subscript>B</subscript> receptors, thereby preventing its deleterious effects and lowering blood pressure. In March 2024, aprocitentan received its first approval in the USA for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other drugs. This article summarizes the milestones in the development of aprocitentan leading to this first approval for hypertension not adequately controlled on other drugs.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Subjects :
- Humans
Endothelin Receptor Antagonists pharmacology
Endothelin Receptor Antagonists therapeutic use
Endothelin Receptor Antagonists administration & dosage
Blood Pressure drug effects
United States
Pyrimidines
Sulfonamides
Drug Approval
Hypertension drug therapy
Antihypertensive Agents pharmacology
Antihypertensive Agents therapeutic use
Antihypertensive Agents adverse effects
Antihypertensive Agents administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1950
- Volume :
- 84
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Drugs
- Publication Type :
- Academic Journal
- Accession number :
- 38833193
- Full Text :
- https://doi.org/10.1007/s40265-024-02053-0